EN
Rapid progress in molecular biology and genetic engineering techniques has made the induction of cell behavior modifications by altering genetic material possible. This allows us to think about the medical application of gene therapy as an alternative to classical pharmacology and as a means of introducing a new approach to treating hereditary diseases. The major obstacle that prevents the application of this method in clinical practice is the difficulty of delivering genetic material to its destination. The fragile DNA molecule (very unstable in in vivo) requires the assistance of supramolecular structures in order to ensure its extended lifetime in circulation. A number of DNA delivery methods have been considered. One of them, a viral carrier, has been extensively studied as a potential candidate for this purpose. Unfortunately, a number of serious problems exist associated with this approach. The risk of accidental infection has not been eliminated and virus presentation causes the immune system to activate. Transfection efficiency achieved with viral vectors is superior to that of other methods, but safety concerns and financial considerations have stimulated studies aimed at the development of non-viral DNA carriers. At present, the transfection efficiency of such carriers is very low. This paper discusses problems encountered when developing a stable and efficient lipid-DNA aggregate, capable of delivering genetic material into the targeted cell nucleus. Discussion is limited to aggregate interaction with the cellular plasma membrane and its fate in the cytosol.